Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. - Wikidata - awgldk - TriplyDB

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.

http://www.wikidata.org/entity/Q27851716

about

The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer Trial watch - inhibiting PARP enzymes for anticancer therapy Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy CIViC database Targeting the RAS oncogene.The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.Therapeutic targeting of cancers with loss of PTEN function.Maximising the potential of AKT inhibitors as anti-cancer treatments Chemoresistance and targeted therapies in ovarian and endometrial cancers Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor Wnt7a Inhibits IL-1β Induced Catabolic Gene Expression and Prevents Articular Cartilage Damage in Experimental Osteoarthritis In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.Stachydrine hydrochloride inhibits proliferation and induces apoptosis of breast cancer cells via inhibition of Akt and ERK pathways Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors Genetically engineered mouse models of PI3K signaling in breast cancer.Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo.AZD5363 Inhibits Inflammatory Synergy between Interleukin-17 and Insulin/Insulin-Like Growth Factor 1 Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.The Akt-mTOR axis is a pivotal regulator of eccentric hypertrophy during volume overload.The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma.AKT signaling in ERBB2-amplified breast cancer.A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type.Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis.Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth Targeting the PI3-kinase/Akt/mTOR signaling pathway.Targeting the PI3K-AKT-mTOR signaling network in cancer.

P2860

Q26744721-D3FF8CB8-68A5-4425-AE09-BA4396B18522 Q26745673-13C3AD91-923A-4649-8FC0-0364667BB05C Q26775940-7F97D56C-EAB0-42D7-B1E5-2B00A5C843E6 Q26798420-063D34DC-FDE2-4C65-9433-42C35DD5D9E7 Q27612411-EEFD9D37-11A0-488C-86D9-D75FE6931A98 Q27687198-80889059-729D-4610-A8B1-7156DADF921E Q27852562-90FFAF9C-40CD-4EE4-B90E-5F66CA7988D5 Q27852764-7874E6E7-D2A4-436A-A679-ADCA26E1DAA5 Q28072254-93C31E52-6D04-4113-A88F-8C231BA72C74 Q28073246-0A8A80DD-8A2E-406C-BBBF-2F5DA8E6F8AE Q28080599-2C1FE0F0-8E50-4FE6-A611-23023331B65F Q28540161-7650BFA6-A9D9-4785-9CA8-0D2399E8E5AD Q29248654-46459889-2AD9-4D72-B0F8-0D646238A353 Q33601377-BAAC2D38-F1DC-4BAA-AAB0-EC2655D4B3A5 Q33623156-41FE7A47-C96D-4005-924C-BBF38236B91D Q33637346-E2498F92-BBA2-46D7-89BA-C249CD08E4BC Q33764664-27EE67C6-5BD0-4916-BEE7-6A66147276FB Q34332175-F66474BE-89B3-4F77-AB73-A2702319816E Q34365942-13804539-894A-49CD-8E65-9490223104DA Q34595624-063DEC66-715A-471C-BF7B-BEFE5E7EC4C7 Q35000243-3876F55E-3D61-4C42-A5AD-481ABEAD27B8 Q35382353-1809F4F1-34F8-48B8-A083-73AAFA172A74 Q35775241-BB467310-732F-4F83-BB60-EB6B7A31B36D Q35849919-7C4BB259-343B-4D12-B9B5-0FB6781A2CA6 Q35980053-7D490BB2-116B-4626-A0FA-F55E110E634B Q36101969-8EF7F49D-508B-4719-96B3-D79FFBB42628 Q36227198-2C483AF4-63E8-4AE6-84A0-2E4C5AE44D65 Q36316643-35B36E2C-C276-402B-B82A-9A0BCE63240C Q36361515-96AD1D73-9290-4F18-99DC-46C6F26A948A Q36382681-F50B54E3-E7DA-40F3-B825-5B6C9521DA2C Q36563578-199909F7-FB1B-490C-8481-9EFDC55BD6D2 Q36640327-1E2B215A-2DDB-4A64-8F0A-2CBF1D0EC572 Q36762858-DA346D73-C348-460F-80ED-6976FF92E7D7 Q36782409-75B32058-AF54-4B16-A1C1-01435B501E00 Q36900522-131031DF-A93D-44F6-B45F-2ECE53B7F777 Q36967905-92BD260A-79EA-4540-90EB-4CDC6861DD7F Q36997524-E0790BE9-1B30-4DC3-A202-456241090FE6 Q37223549-241B9B1B-DCCC-4FB2-A21A-E79AC34F6960 Q37265126-E40EE83F-B6F1-46C8-A6F6-8D8848E2B11E Q37353968-CE702575-F098-453A-B9DD-80EFE59A1BB8

P2860

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.

http://www.wikidata.org/entity/Q27851716

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Preclinical pharmacology of AZ ...... ivity with genetic background.

@ast

Preclinical pharmacology of AZ ...... ivity with genetic background.

@en

Preclinical pharmacology of AZ ...... ivity with genetic background.

@nl

type

label

Preclinical pharmacology of AZ ...... ivity with genetic background.

@ast

Preclinical pharmacology of AZ ...... ivity with genetic background.

@en

Preclinical pharmacology of AZ ...... ivity with genetic background.

@nl

altLabel

Preclinical pharmacology of AZ ...... tivity with genetic background

@en

prefLabel

Preclinical pharmacology of AZ ...... ivity with genetic background.

@ast

Preclinical pharmacology of AZ ...... ivity with genetic background.

@en

Preclinical pharmacology of AZ ...... ivity with genetic background.

@nl

P1433

Q27851716-03D46A0D-B8C5-4352-93EE-74C260531602

P1476

Q27851716-6C8DA75B-0C85-4850-92D8-179624EA02DC

P2093

Q27851716-0AF9C8A2-98D5-4D34-83D1-4C12F03BCC3F

Q27851716-0C8A521E-9744-4B7F-96A1-347324BB6900

Q27851716-10AA50ED-6B2D-4A23-B631-47A28FF10B21

Q27851716-1455DAE9-A293-40BF-95E9-98F37F54F7A0

Q27851716-2383F199-FC3B-4D36-BB30-B36F083B5A5C

Q27851716-25C27A41-4991-444E-942A-E8A417E60A62

Q27851716-366FF9A0-A3C9-46E4-B561-54F9BB1E39DC

Q27851716-38F2038B-1137-4C6B-8E6B-7DFAA7F58E53

Q27851716-4BD96620-CDDF-49FE-962F-79DC82CD96BA

Q27851716-5ABEE5DB-5ED0-44B7-AD90-F48117DE65CD

P304

Q27851716-1937F9AC-A37A-419E-B16E-6790E8B4EB14

P31

Q27851716-B988D055-AEF1-4A9C-8BF1-40652688EC28

P3181

Q27851716-6A7C7853-F5FC-4351-8C96-ECCB352A5906

P356

Q27851716-F824B5F6-9597-4868-B3DD-06EB29B39A29

P407

Q27851716-B2BD7A2A-B20D-4793-8C70-319DF175E9CE

P433

Q27851716-42CFEF6F-131D-4400-91E6-C6D21B129E36

P478

Q27851716-53000274-7311-45B5-A318-D0802CBC8B0E

P577

Q27851716-B6B0FD75-AC5C-4E94-996F-4BF39CB4026A

P5875

Q27851716-B4C962CB-CA58-44A0-8AFE-05562378C281

P698

Q27851716-A6411A68-6882-4DAA-BFCD-922B699F2FDF

P921

Q27851716-30F753EA-859F-432F-A023-614841477ACF

Q27851716-961AFDEF-F141-41AC-B480-6773DF24E14E

P3181

P356

1535-7163.MCT-11-0824-T

P1433

Molecular Cancer Therapeutics

P1476

Preclinical pharmacology of AZ ...... ivity with genetic background.

@en

P2093

Barry R Davies

http://www.w3.org/2001/XMLSchema#string

Beirong Gao

http://www.w3.org/2001/XMLSchema#string

Christine C Chresta

http://www.w3.org/2001/XMLSchema#string

Claire Crafter

http://www.w3.org/2001/XMLSchema#string

Clare Lane

http://www.w3.org/2001/XMLSchema#string

Darren Cross

http://www.w3.org/2001/XMLSchema#string

De-Hua Yu

http://www.w3.org/2001/XMLSchema#string

Donald Ogilvie

http://www.w3.org/2001/XMLSchema#string

Hannah Greenwood

http://www.w3.org/2001/XMLSchema#string

James Yates

http://www.w3.org/2001/XMLSchema#string

P304

873-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1200322

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1535-7163.MCT-11-0824-T

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221795911

http://www.w3.org/2001/XMLSchema#string

P698

22294718

http://www.w3.org/2001/XMLSchema#string

P921

pharmacodynamics